Margaret C. Frame

This study screens a large compound library across patient-derived GBM stem cells to identify effective drugs targeting tumor heterogeneity and presents validated hits for further exploration.

This study shows that systemic FAK inhibition reduces immunosuppressive macrophages in glioblastoma by blocking monocyte trafficking, enhancing T cell activity and improving survival in a mouse model.

This study shows FAK regulates glycolysis and glutamine oxidation in glioblastoma stem cells, affecting mitochondrial morphology and cell migration.

This study identifies a synergistic combination of FAK and MEK inhibitors that effectively targets glioblastoma heterogeneity and improves therapeutic outcomes.

This study shows that collagen scar formation during bile duct regeneration alters biomechanical properties, activating integrin-SRC/FAK signaling to drive ductular regeneration through a leading-tip of integrin-2-high cells.

The paper identifies context-dependent gene essentiality in GBM using CRISPR screening and develops a platform to link biomarkers to therapeutic targets.

This study shows FAK regulates IL-33 expression by controlling chromatin accessibility at c-Jun motifs through ATAC-seq and RNA-seq integration.